Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006

Aihua Wang, Yanyan Wang, Yu Yao, Zizhen Xu, Li Zhou, Li Wang, Li Zhang, Yu Chen, Zhixiang Shen, Jiong Hu, Junmin LiJournal of Experimental & Clinical Cancer Research 2010 · DOI

Abstract The number of new patients arising in Shanghai increased from 2001 to 2006. There were still patients receiving hydroxyurea and IFN-alpha. As the first-line regime for CML, imatinib was less administered in Shanghai before, but has received considerable development and great responses since 2003.

Introduction

Chronic Myeloid Leukemia (CML) is a hematologic malignancy driven by the Philadelphia chromosome, a genetic translocation that creates the BCR-ABL fusion gene. This gene produces a mutant tyrosine kinase protein that causes white blood cells to proliferate uncontrollably. Before the early 2000s, treatment options in Shanghai were largely limited to hydroxyurea, interferon-alpha (IFN-α), or high-risk hematopoietic stem cell transplantation (HSCT). This retrospective study tracks the pivotal transition to targeted therapy with imatinib between 2001 and 2006, documenting real-world epidemiological trends and clinical outcomes.

Methods

Researchers conducted a retrospective review of 615 primary CML patients across 21 hospitals in Shanghai. Patients were grouped by their primary treatment regimen (Hydroxyurea, IFN-α, Imatinib, or HSCT) and staged into Chronic Phase (CP), Accelerated Phase (AP), or Blastic Crisis (BC). Key metrics included Complete Hematologic Response (CHR), Complete Cytogenetic Response (CCyR), and Overall Survival (OS) calculated via Kaplan-Meier curves.

The study identified a significant demographic profile in the Shanghai population. CML primarily afflicted individuals aged 40–60, which is notably younger than the median age of diagnosis typically reported in Western populations (60+).

Age distribution of CML patients in Shanghai showing a peak in the 40-60 age range.

Treatment Efficacy and Survival

Imatinib demonstrated superior efficacy compared to traditional regimens. In Chronic Phase patients, it induced a 92.2% CHR and a 64.3% CCyR. Survival data further underscored this advantage: the estimated 5-year Overall Survival for the imatinib group was 85.1%, compared to 51.2% for those on IFN-α.

Kaplan-Meier survival curves comparing Imatinib, HSCT, and Interferon treatments.

While HSCT also showed high survival, imatinib provided a non-invasive alternative with manageable side effects. The median time to reach CCyR was also significantly shorter with imatinib (9 months) than with interferon (24 months).

Discussion and Limitations

The adoption of imatinib in Shanghai surged after 2003 following the introduction of patient assistance programs, highlighting the impact of economic accessibility on clinical outcomes. However, the study notes limitations such as a relatively short median follow-up for some cohorts and the emergence of drug resistance due to BCR-ABL mutations. Future management strategies will likely involve second-generation TKIs to address resistant cases.

Summary updated

Abstract

The number of new patients arising in Shanghai increased from 2001 to 2006. There were still patients receiving hydroxyurea and IFN-alpha. As the first-line regime for CML, imatinib was less administered in Shanghai before, but has received considerable development and great responses since 2003.
BibTeX
@article{wang2010summary,
  author = {Aihua Wang and Yanyan Wang and Yu Yao and Zizhen Xu and Li Zhou and Li Wang and Li Zhang and Yu Chen and Zhixiang Shen and Jiong Hu and Junmin Li},
  title = {{Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2010},
  doi = {10.1186/1756-9966-29-20},
}
Figure